Study Reveals Significant Risk Reduction with Elixir Medical Bioadaptor
Elixir Medical announced new clinical results for its DynamX bioadaptor coronary implant system, featuring a novel design to restore blood flow and treat coronary artery disease (CAD) symptoms.
The sirolimus-eluting DynamX bioadaptor addresses existing issues with stent devices, allowing the artery to heal and return to natural motion after support is no longer needed.
The company received FDA breakthrough device designation for DynamX last year and has a CE mark, although it remains investigational in the U.S.
Elixir Medical’s DynamX bioadaptor aims to return the diseased vessel to a more normal condition.
The company shared positive findings for the system in May, highlighting its potential to unlock, adapt, and promote arterial healing.
Author's summary: Elixir Medical's DynamX bioadaptor shows promise.
More News
- SVFD recognizes fire prevention poster winners
- Pre-school praised for 'working hard to improve' with exemplary Ofsted report
- 5 Must See Earnings Charts That Aren
- 'Surreal' for Jones to see Cherries' journey in nine years at club
- 'What a player': Adams praises Kroupi's mentality - “his ceiling is really high”
- How to watch Texas high school volleyball: Schulenburg vs. Yorktown, Oct. 30
- Wow — Sixers erase 19-point deficit, beat Wizards in OT to move to 4-0
- Mayor Johnson’s record-setting $1 billion TIF surplus highlights issues
- Ladycats fall to Schulenburg in five sets
- Hauser headlines Noosa Triathlon as Gentle squeezed out